State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Shawn Dason(The Ohio State University), Karie Runcie(Columbia University Irving Medical Center), Eric A. Singer(Rutgers Cancer Institute of New Jersey), Raquibul Hannan(The University of Texas Southwestern Medical Center), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center)
Cited by 38
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
|European Journal of Nuclear Medicine and Molecular Imaging|2013|183
Differential effects of sucrose and fructose on dietary obesity in four mouse strains
|Physiology & Behavior|2010|75
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
|Annals of Oncology|2024|66
Therapeutic advances in leiomyosarcoma
|Frontiers in Oncology|2023|49